270 related articles for article (PubMed ID: 12085010)
41. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro.
Sakuma S; Kato Y; Nishigaki F; Magari K; Miyata S; Ohkubo Y; Goto T
Int Immunopharmacol; 2001 Apr; 1(4):749-57. PubMed ID: 11357886
[TBL] [Abstract][Full Text] [Related]
42. Regulation of the Ca
Sánchez-Solano A; Corral N; Segura-Covarrubias G; Guzmán-Hernández ML; Arechiga-Figueroa I; Cruz-Rangel S; Pérez-Cornejo P; Arreola J
Cell Calcium; 2020 Jul; 89():102211. PubMed ID: 32422433
[TBL] [Abstract][Full Text] [Related]
43. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.
Sakuma S; Kato Y; Nishigaki F; Sasakawa T; Magari K; Miyata S; Ohkubo Y; Goto T
Br J Pharmacol; 2000 Aug; 130(7):1655-63. PubMed ID: 10928971
[TBL] [Abstract][Full Text] [Related]
44. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
Holländer GA; Bierer BE; Burakoff SJ
Transfus Sci; 1994 Sep; 15(3):207-20. PubMed ID: 10155542
[TBL] [Abstract][Full Text] [Related]
45. Physiological function of FKBP12, a primary target of rapamycin/FK506: a newly identified role in transcription of ribosomal protein genes in yeast.
Kasahara K
Curr Genet; 2021 Jun; 67(3):383-388. PubMed ID: 33438053
[TBL] [Abstract][Full Text] [Related]
46. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.
Annett S; Moore G; Robson T
Pharmacol Ther; 2020 Nov; 215():107623. PubMed ID: 32622856
[TBL] [Abstract][Full Text] [Related]
47. Establishment of a cell model based on FKBP12 dimerization for screening of FK506-like neurotrophic small molecular compounds.
Xiao H; Wang LL; Shu CL; Yu M; Li S; Shen BF; Li Y
J Biomol Screen; 2006 Apr; 11(3):225-35. PubMed ID: 16490780
[TBL] [Abstract][Full Text] [Related]
48. Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations.
Silva ND; Prendergast FG
Biophys J; 1996 Mar; 70(3):1122-37. PubMed ID: 8785272
[TBL] [Abstract][Full Text] [Related]
49. Propagation of conformational instability in FK506-binding protein FKBP12.
LeMaster DM; Bashir Q; Hernández G
Biochim Biophys Acta Proteins Proteom; 2024 May; 1872(3):140990. PubMed ID: 38142946
[TBL] [Abstract][Full Text] [Related]
50. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
51. The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells.
Romano S; Mallardo M; Chiurazzi F; Bisogni R; D'Angelillo A; Liuzzi R; Compare G; Romano MF
Haematologica; 2008 Jul; 93(7):1039-48. PubMed ID: 18492692
[TBL] [Abstract][Full Text] [Related]
52. The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons.
Avramut M; Zeevi A; Achim CL
Brain Res Dev Brain Res; 2001 Dec; 132(2):151-7. PubMed ID: 11744119
[TBL] [Abstract][Full Text] [Related]
53. Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein.
Chambraud B; Radanyi C; Camonis JH; Rajkowski K; Schumacher M; Baulieu EE
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2104-9. PubMed ID: 10051602
[TBL] [Abstract][Full Text] [Related]
54. Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin.
Xu Q; Liang S; Kudla J; Luan S
Plant J; 1998 Aug; 15(4):511-9. PubMed ID: 9753776
[TBL] [Abstract][Full Text] [Related]
55. Association of immunophilins with mammalian TRPC channels.
Sinkins WG; Goel M; Estacion M; Schilling WP
J Biol Chem; 2004 Aug; 279(33):34521-9. PubMed ID: 15199065
[TBL] [Abstract][Full Text] [Related]
56. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).
De Angelis B; Dotti G; Quintarelli C; Huye LE; Zhang L; Zhang M; Pane F; Heslop HE; Brenner MK; Rooney CM; Savoldo B
Blood; 2009 Nov; 114(23):4784-91. PubMed ID: 19759356
[TBL] [Abstract][Full Text] [Related]
57. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes.
Dutz JP; Fruman DA; Burakoff SJ; Bierer BE
J Immunol; 1993 Apr; 150(7):2591-8. PubMed ID: 7681074
[TBL] [Abstract][Full Text] [Related]
58. FK506 and the role of immunophilins in nerve regeneration.
Gold BG
Mol Neurobiol; 1997 Dec; 15(3):285-306. PubMed ID: 9457703
[TBL] [Abstract][Full Text] [Related]
59. FK506-binding protein 12 ligands: a patent review.
Liu F; Wang YQ; Meng L; Gu M; Tan RY
Expert Opin Ther Pat; 2013 Nov; 23(11):1435-49. PubMed ID: 23957229
[TBL] [Abstract][Full Text] [Related]
60. Competitive and slow-binding inhibition of calcineurin by drug x immunophilin complexes.
Salowe SP; Hermes JD
Arch Biochem Biophys; 1998 Jul; 355(2):165-74. PubMed ID: 9675023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
